Verona Pharma plc (VRNA) Announces Proposed Stock Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- S&P Global shares rise on report of possible CapIQ spinoff
Verona Pharma plc Announces Proposed Underwritten Public Offering
August 9, 2022 4:16 PM EDTLONDON and RALEIGH, N.C., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (Verona Pharma or the Company), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announced a proposed underwritten public offering of 10 million American Depositary Shares (ADSs), each representing eight ordinary shares of Verona Pharma, nominal value £0.05 per share (the Offering). All ADSs in the Offering will be offered by Verona Pharma. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to... More
